Avai BioAVAI -6.86%24 EV-to-EBITDA is -19.03 as of Jul. 07, 2026. GuruFocus rates AVAI with a GF Score™ of 24/100. The stock has 3 warning signs investors should review. Among 1,939 Software companies, Avai Bio ranks worse than 51572.92% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Avai Bio's enterprise value is $18.91 Mil.
Avai Bio's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.99 Mil. Therefore, Avai Bio's EV-to-EBITDA for today is -19.03.
The historical rank and industry rank for Avai Bio's EV-to-EBITDA or its related term are showing as below:
AVAI'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -3283.3 Med: -64.82 Max: 2925.28
Current: -19.03
During the past 8 years, the highest EV-to-EBITDA of Avai Bio was 2925.28. The lowest was -3283.30. And the median was -64.82.
AVAI's EV-to-EBITDA is ranked worse than 100% of 1939
companies
in the Software industry
Industry Median: 10.51
vs AVAI: -19.03
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Avai Bio (OTCPK:AVAI) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Avai Bio's share price for today is $0.12564.
Avai Bio's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.000.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Avai Bio's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Software - Application subindustry, Avai Bio's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Avai Bio EV-to-EBITDA vs Software Industry
For the Software industry and Technology sector, Avai Bio's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Avai Bio's EV-to-EBITDA falls into.
Avai Bio's current Enterprise Value is $18.91 Mil.
Avai Bio's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.99 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Avai Bio (AVAI) has a EV-to-EBITDA of -19.03 as of Jul. 07, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Avai Bio. According to the industry distribution chart, Avai Bio ranks #999999 out of 1939 companies in the Software industry.
Is Avai Bio's EV-to-EBITDA too high?
Avai Bio's current EV-to-EBITDA is -19.03. Based on the distribution chart, Avai Bio ranks #999999 out of 1939 companies in the Software industry, which is in the bottom quartile relative to peers. Overall, Avai Bio has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Avai Bio's EV-to-EBITDA compare to IPM and RCT?
According to the Software industry distribution chart, Avai Bio ranks #999999 out of 1939 companies for EV-to-EBITDA. This places Avai Bio in the lower half of its industry. The industry median EV-to-EBITDA is 10.51. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Software company?
The median EV-to-EBITDA among Software companies is 10.51, based on 1,939 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Avai Bio. For the Software industry, the median EV-to-EBITDA is 10.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Avai Bio's current EV-to-EBITDA is -19.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avai Bio stock overvalued right now?
Avai Bio (AVAI) has a current EV-to-EBITDA of -19.03. The current EV-to-EBITDA is -19.03. Avai Bio's overall GF Score™ is 24/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Avai Bio (AVAI), the current EV-to-EBITDA is -19.03 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Avai Bio Inc is a biotechnology company focused on identifying genetically modified cell lines, and through joint venture and licensing agreements, developing cell-based therapies. The company has two development programs in its cellular therapies pipeline, a diabetes development program to advance a treatment for type 1 and type 2 insulin-dependent diabetes, and an ?-Klotho protein development program to advance therapies for age-related diseases and anti-aging treatments.
24GF Score
Get the complete analysis for AVAI
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AVAI has been successfully added to your 
